Eosinophilic cryptitis

Summary

Eosinophilic cryptitis (MONDO:0023073) is a disease. A subtype of cystitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eosinophilic cryptitis
Mondo ID	MONDO:0023073
SNOMED CT	445918001
UMLS	C0742965
MedGen	148162
Is cancer (heuristic)	no

Also known as: eosinophilic cystitis

Disease family

This is a subtype of cystitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › cystitis › eosinophilic cryptitis

Related subtypes (13): hemorrhagic cystitis, prostatocystitis, acute cystitis, diphtheritic cystitis, trigonitis, radiation cystitis, cystitis cystica, emphysematous cholecystitis, chronic cystitis, acalculous cholecystitis, gonococcal cystitis, pyelocystitis, Trichomonas cystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.